COMPARE · Data as of August 21, 2026
DXCM vs STVN
Verdict: Side-by-side breakdown using the Bull Rankings model. DXCM scored 77.5, STVN scored 63.4 — DXCM leads.
Compare another set
Different reporting periods. DXCM's fundamentals are as of June 2026, but STVN's are as of December 2025 — a 6-month gap. Growth, margin and valuation figures below therefore describe different windows and aren't strictly like-for-like.
DXCM
DexCom, Inc.
77.5
$92.34 · $34.8B
fundamentals as of
Score gap
14.1
DXCM leads
STVN
Stevanato Group S.p.A.
63.4
$22.60 · $6.2B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
- Fastest growthDXCM+15.5%
- Strongest balance sheetSTVN0.29
- Highest qualityDXCM91 / 100
Side by side · every name on one set of axes
The model, pillar by pillar (0–100 each)
DXCM
stronger →← stronger
STVN
91
Qualityreturns · margins · balance sheet
52
89
Growthrevenue & earnings expansion
75
58
Valuevaluation vs sector peers
76
DXCM is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
DXCM
STVN
$1.4bC+
FCF
-$36mF
+15.5%B+
Rev
+7.4%B
0.53B
D/E
0.29B
36.5xC+
P/E
—
1.70C+
PEG
0.37A
—
P/S
4.3xB
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
DXCM
STVN
64% above
Price vs fair valuelower is cheaper
—
~24%/yr
Growth the price implies10-yr FCF · lower = less priced in
—
-49%
1-yr DCF upside
—
-39%
5-yr DCF upside
—
-22%
10-yr DCF upside
—
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
DXCM
Why this score
- Buying back stock
- Durable high returns
STVN
Why this score
- Foreign reporter (EUR)
The companies
DXCMDexCom, Inc.
Why now
Medical Devices · market cap $34.8b. Trading near 52-week high of $92.56 — momentum setup, limited technical margin of safety. Revenue growing +16%, comfortably above the S&P median. 25 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $94.12 (implying +2% upside).
Moat
Net margin 20% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 38% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 141% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Trading within 0% of the 52-week high — limited technical margin of safety; a momentum reversal would test conviction. Beta 1.41 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return. Trailing P/E 36x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates.
STVNStevanato Group S.p.A.
Why now
Medical Instruments & Supplies · market cap $6.2b. 19% off the 52-week high of $28.00. PEG 0.37 — paying under fair value for the growth rate. 11 sell-side analysts rate this a Buy with a mean 1-yr target of $24.83 (implying +10% upside).
Moat
Higher-variance name — the moat signals on the quantitative card are modest, so the durability case rests on execution (turning current growth into durable earnings power) or an un-monetized asset (IP / network effects / first-mover position) rather than an entrenched competitive position.
Risk
Free cash flow is negative (-$36m) — capital raises or debt issuance likely required; dilution / leverage risk. Trailing P/E 40x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where DXCM and STVN diverge
On the headline score the gap is 14.1 points in favor of DXCM. They get there differently, though — each leads on a different pillar, so the better pick depends on which you weight.
- QualityDXCM 90.6 · STVN 52.1DXCM +38.5
- ValueDXCM 57.6 · STVN 75.6STVN +18.0
- GrowthDXCM 89.5 · STVN 75.4DXCM +14.1
Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.